Clinical Trial Update: Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating long-term safety, tolerability, and efficacy of iptacopan in participants with atypical hemolytic uremic syndrome is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atypical Hemolytic Uremic Syndrome | Phase 3 | Status: RECRUITING